You are here: Industry Insights > Zulresso

News List

Sage strategy for postpartum depression drug Zulresso keys on patient support fiercepharma
July 04, 2019
Postpartum depression is complex—and so is the first FDA-approved treatment. The 60-hour inpatient infusion process for Sage Therapeutics' Zulresso calls for more than the typical information and education.
Sage Therapeutics' Zulresso becomes first treatment for post-partum depression approved in US firstwordpharma
March 20, 2019
The FDA announced Tuesday that it has cleared Sage Therapeutics' Zulresso (brexanolone) to treat postpartum depression (PPD) in adult women, making it the first drug approved in the US specifically for this indication.
Sage wins OK for depression drug Zulresso. Up next? Major marketing challenges fiercepharma
March 20, 2019
Sage Therapeutics has the first-ever approval for a prescription drug for postpartum depression, thanks to the FDA’s Tuesday nod for Zulresso. But it also has a number of big challenges ahead.
Sage wins OK for depression drug Zulresso fiercepharma
March 20, 2019
Up next? Major marketing challenges
FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression drugs
March 20, 2019
The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD.
Sage soars on postpartum depression data pharmaphorum
January 10, 2019
Sage Therapeutics has scored a big win with postpartum depression (PPD) drug SAGE-217, after rolling the dice on an upgraded clinical trial last summer.